Dr. Doebele Discusses Brain Metastases in ROS1+ NSCLC

Robert C. Doebele, MD, PhD
Published: Monday, Oct 30, 2017



Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non–small cell lung cancer (NSCLC).

Crizotinib (Xalkori), the current standard of care, does not have good central nervous system (CNS) penetration; therefore, CNS metastases cannot be well controlled. However, entrectinib is a very CNS-penetrant brain metastases-active compound, says Doebele.

Entrectinib may allow for better upfront control of existing brain metastases, and may prevent the development of brain metastases in the future.
SELECTED
LANGUAGE


Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non–small cell lung cancer (NSCLC).

Crizotinib (Xalkori), the current standard of care, does not have good central nervous system (CNS) penetration; therefore, CNS metastases cannot be well controlled. However, entrectinib is a very CNS-penetrant brain metastases-active compound, says Doebele.

Entrectinib may allow for better upfront control of existing brain metastases, and may prevent the development of brain metastases in the future.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x